ASIC3 or TRPV1 deficiency attenuated arthritis-associated hyperalgesia in the chronic phase (after 6 or 8 weeks) and TDAG8 knockout attenuated the hyperalgesia in the acute and chronic phases, but TDAG8 knockdown only attenuated acute phase (before 4 weeks) of RA pain. This evidence concerns the gene TRPV1 and arthritic joint disease.